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Objectives The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident
heart failure (HF) in the community.
Background Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important
mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown.
Methods Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59
years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression.
Results Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p 
0.001); this association was attenuated in multivariate analyses (p  0.06). A total of 166 participants devel-
oped incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for
incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43;
p  0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR:
1.23; 95% CI: 1.04 to 1.47; p  0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-
adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p  0.01). The addition of Gal-3 to clinical factors resulted in negligible
changes to the C-statistic and minor improvements in net reclassification improvement.
Conclusions Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and
mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the
role of Gal-3 in the pathophysiology of HF. (J Am Coll Cardiol 2012;60:1249–56) © 2012 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.053Heart failure (HF) accounts for more than 1 million
hospital admissions per year, with an estimated cost exceed-
ing $39 billion annually in the U.S. (1). The development of
HF is often a clinically silent process, with progressive
cardiac remodeling that eventually leads to symptomatic
presentation late in the course of disease progression. After
HF diagnosis, nearly 60% of men and 45% of women will
die within 5 years (1). Although most therapies are imple-
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sive remodeling has already occurred, strategies that target
patients with cardiac remodeling before the onset of symp-
toms may prevent complications associated with HF (2,3).
Cost-effective strategies to identify this subgroup of patients
are of great interest, as outlined in the American College of
Cardiology and American Heart Association guidelines (4).
See page 1257
Although cardiac imaging of the general population is not
recommended, a biomarker strategy to screen and identify
patients to refer for diagnostic noninvasive cardiac imaging
may be useful (5). This may facilitate the early recognition
of asymptomatic left ventricular (LV) dysfunction and the
initiation of therapy to favorably alter the course of progres-
sion to HF.
Cardiac fibrosis is an important contributor to the patho-
physiology of LV systolic and diastolic dysfunction. It is also
a pathologic phenomenon common to cardiac remodeling
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and other conditions affecting the
myocardium. Galectin-3 (Gal-3) is
a beta-galactoside-binding lectin
that appears to be a mediator of
cardiac fibrosis in a number of
recent experimental studies (6,7).
Gal-3 has been related to mor-
tality in patients with acute and
chronic HF (8–11), as well as in
the general population (12). The
role of Gal-3 as a predictor of
incident HF in apparently healthy
subjects has not been studied. We
sought to examine the clinical cor-
relates of Gal-3 to explore mech-
anisms by which Gal-3 may be
associated with an adverse cardio-
vascular prognosis. We also exam-
ined the cross-sectional relations
of Gal-3 to LV structure and func-
tion, to assess whether Gal-3 is associated with subclinical
changes in cardiac function. Last, we sought to study the
association of Gal-3 levels and incident HF events in the
community. We hypothesized that Gal-3, a prognostic
biomarker in patients with HF, would be associated with
incident HF.
Methods
Participants. The Framingham Heart Study is a longitu-
dinal community-based cohort initiated in 1948 to prospec-
tively study cardiovascular disease and associated risk fac-
tors. The Framingham Offspring Cohort includes children
(and spouses of children) of the original cohort participants,
and participants have been examined approximately every 4
years since its inception in 1971 (13). Each examination
includes routine questionnaires, physical examination, an-
thropometry, and blood testing. Gal-3 levels were measured
at the sixth examination (1995 to 1998). Of 3,450 partici-
pants with sample available for Gal-3 measurement, a total
of 97 participants were excluded because of prevalent HF
(n  40), stage IV kidney disease (n  10), missing
covariates (n  39), missing Gal-3 measurements (n  2),
and extreme Gal-3 outliers (5 log SDs above or below the
log-transformed mean, n  6, specified a priori), leaving
3,353 participants (97%) for analysis.
Biomarker measurement. Blood samples were collected
after an overnight fast and immediately centrifuged and
stored at 70°C until assayed. Plasma concentrations of
Gal-3 were measured using an enzyme-linked immunosor-
bent assay (BG Medicine, Waltham, Massachusetts) (14).
The lower detection limit was 1.32 ng/ml, with an upper
detection limit of 96.6 ng/ml. Across this measurement
range, the within-run and total precision are reported
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
Gal-3  galectin-3
HF  heart failure
HR  hazard ratio
IDI  integrated
discrimination improvement
LV  left ventricular
LVDD  left ventricular
end-diastolic dimension
NRI  net reclassification
improvementbetween 2.1% and 5.7% and 4.2% and 12.0%, respectively(14). B-type natriuretic peptide (BNP) was previously mea-
sured (15).
Clinical assessment. Participants underwent a compre-
hensive clinical assessment at the sixth Offspring Cohort
examination (13). Hypertension was defined as a systolic
blood pressure 140 mm Hg, a diastolic blood pressure
90 mm Hg, or current antihypertensive drug treatment.
Cardiovascular events were adjudicated by a 3-physician
panel after review of medical records. History of coronary
heart disease included prior myocardial infarction, acute
coronary insufficiency (prolonged ischemic symptoms with
new electrocardiographic abnormalities in the absence of
biomarker elevations indicative of infarction), or angina
pectoris. Atrial fibrillation was determined after examining
all available electrocardiograms. Valvular heart disease was
defined as a systolic murmur of grade 3/6 or higher or any
diastolic murmur. Total and high-density lipoprotein cho-
lesterol levels were measured. Diabetes mellitus was defined
as a fasting glucose level 126 mg/dl, nonfasting glucose
200 mg/dl, or the use of insulin or oral hypoglycemic
medications. Estimated glomerular filtration rate (eGFR)
was calculated using the Modification of Diet in Renal
Disease equation (16).
Definition of HF. At each follow-up examination or
health update, interim cardiovascular disease events were
identified and medical records obtained. Initial HF was
confirmed by a panel of 3 physicians after systematic review
of outpatient and hospital records using established proto-
cols and Framingham criteria (17). The present study
included initial HF events occurring between the baseline
examination (1995 to 1998) through the end of 2008 as
incident events.
Echocardiographic methods. A total of 2,425 participants
with Gal-3 measurements also underwent routine M-mode
and 2-dimensional echocardiography (18) and had complete
data for analysis. LV end-diastolic dimension (LVDD), LV
end-systolic dimension, left atrial end-systolic diameter, and
end-diastolic LV septal and posterior wall thicknesses were
measured according to American Society of Echocardiog-
raphy guidelines (19). Fractional shortening was calculated as:
[(LVDD  LV end-systolic dimension)/LVDD]  100, and
LV systolic dysfunction was defined as fractional shortening
29%. LV mass was calculated as: 0.8{1.04[(LVDD  LV
posterior wall thickness  LV septal wall thickness)3 
VDD3]} 0.6 (20). LV mass was indexed to height2.7 (21),
and elevated LV mass was defined as an indexed value greater
than or equal to the sex-specific 80th percentile.
Statistical analysis. Because of non-normality, Gal-3,
eGFR, and BNP were log transformed for subsequent
analyses. Baseline clinical characteristics were summarized
by sex-specific quartiles of log Gal-3 and trends in means
across quartiles examined. Multivariate regression analysis
of Gal-3 correlates was performed using a stepwise selection
model with inclusion of variables at p 0.05. Because of sex
differences in Gal-3 distribution, sex-standardized log
Gal-3 was used for correlation and regression analyses.
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structure and function (including LV mass, left atrial
end-systolic diameter, and LV fractional shortening) were
examined using linear regression models adjusting for:
1) age, sex, and height; and 2) age, sex, height, systolic blood
pressure, antihypertensive medication use, diabetes mellitus,
and previous myocardial infarction. Analyses of fractional
shortening were not adjusted for height, and analyses of left
atrial end-systolic diameter were also adjusted for valvular
heart disease. Participants with prevalent atrial fibrillation
were excluded from echocardiographic analyses.
Crude HF incidence rates were estimated by sex-specific
Gal-3 quartile. The cumulative incidence of HF across
Gal-3 quartiles was examined using a Kaplan-Meier-like
method while accounting for competing risk for death (22).
Multivariable Cox proportional hazards regression models
were constructed to evaluate the association of Gal-3 with
incident HF events and with all-cause mortality (23).
Models were created adjusting for 1) age and sex; 2) age,
sex, systolic blood pressure, antihypertensive medication
use, body mass index, diabetes mellitus, current smoking
status, prevalent coronary heart disease, valvular heart dis-
ease, and atrial fibrillation; and 3) all covariates in model 2
plus BNP. Proportional hazards assumptions were met.
Analyses for mortality were further adjusted for eGFR and
total and high-density lipoprotein cholesterol. In secondary
analyses, we examined the association of Gal-3 and cardio-
vascular death (defined as death from coronary heart disease,
cerebrovascular disease, or other cardiovascular cause), ad-
justing for the same covariates as analyses for all-cause
mortality.
Baseline Characteristics of 3,353 Participants by Sex-Specific Gal-Table 1 Baseline Characteristics of 3,353 Participants by Sex-
Characteristic 1 (n  835) 2 (n
Clinical
Age (yrs) 55 9 58
Women 454 (54%) 431
Systolic blood pressure (mm Hg) 124 18 127
Diastolic blood pressure (mm Hg) 75 9 76
Antihypertensive medication use 134 (16%) 193
Diabetes mellitus 56 (7%) 66
Coronary heart disease 32 (4%) 40
Body mass index (kg/m2) 26.9 (4.7%) 27.6
Smoking 121 (14%) 132
Laboratory
Total cholesterol (mg/dl) 200 36 205
HDL cholesterol (mg/dl) 54 17 52
eGFR (ml/min/1.73 m2) 94 22 90
BNP (pg/ml) 12.8 15.6 13.7
Echocardiography (n  2,425)*
Left ventricular mass (g/m2) 156 42 159
Fractional shortening (%) 37.1 5.2 37.1
Left atrial dimension (mm) 39.0 5.0 39.3
Values are mean SD or n (%). *Lower and upper limits for Gal-3 quartiles for men and women w
ng/ml; and quartile 4, 15.4 to 47.7 ng/ml; women: quartile 1, 5.0 to 12.0 ng/ml; quartile 2, 12.0 to 14.
BNP  B-type natriuretic peptide; eGFR  estimated glomerular filtration rate; Gal-3  galectin-3; HWe adjusted HF analyses for eGFR in secondary analy-
ses, because changes in kidney function may mediate Gal-3
effects on incident HF. We conducted sensitivity analyses,
excluding 283 patients with prevalent chronic kidney disease
(CKD; defined as eGFR 60 ml/min/1.73 m2), and we
sed a time-dependent covariate to adjust for incident CKD
vents in analyses for both incident HF and mortality.
To assess the incremental benefit of Gal-3 in the predic-
ion of HF and mortality risk, C-statistics were compared
etween models with traditional risk factors with and
ithout Gal-3 (24). We estimated the integrated discrimi-
ation improvement (IDI) and the category-free net reclas-
ification improvement (NRI) metric for the addition of
al-3 in fully adjusted models (25,26). All statistical anal-
ses were conducted using SAS version 9.2 for Windows
SAS Institute Inc., Cary, North Carolina).
esults
he baseline clinical characteristics of 3,353 participants are
isplayed by Gal-3 quartiles in Table 1. The mean age was
9 years, and 53% of participants were women. The distri-
ution of Gal-3 levels in our sample is shown in Online
igure 1. Gal-3 concentrations were higher in women
ompared with men (p  0.05), with a median Gal-3 level
n women of 14.3 ng/ml (interquartile range: 12.0 to 16.8
g/ml) versus 13.1 ng/ml (interquartile range: 11.1 to 15.4
g/ml) in men. Participants with higher Gal-3 levels were
lder and had a higher prevalence of traditional cardiovas-
ular risk factors, including hypertension, diabetes mellitus,
artileific Gal-3 Quartile
uartile of Gal-3*
p for Trend) 3 (n  842) 4 (n  834)
60 9 64 10 0.0001
436 (52%) 461 (55%) 0.98
130 19 132 20 0.0001
76 9 75 10 0.34
250 (30%) 355 (43%) 0.0001
81 (10%) 115 (14%) 0.0001
66 (8%) 106 (13%) 0.0001
) 28.5 (5.2%) 28.6 (5.3%) 0.0001
149 (18%) 109 (13%) 0.63
209 37 208 42 0.0001
51 16 48 15 0.0001
88 25 80 25 0.0001
14.7 18.3 22.4 30.6 0.0001
163 45 166 45 0.0001
37.1 5.4 37.3 6.2 0.59
39.3 5.1 40.0 5.4 0.001
ollows: men: quartile 1, 3.9 to 11.1 ng/ml; quartile 2, 11.1 to 13.1 ng/ml; quartile 3, 13.1 to 15.43 QuSpec
Q
 842
 9
(51%)
 18
 9
(23%)
(8%)
(5%)
(5.1%
(16%)
 37
 16
 24
 17.7
 44
 5.7
 5.2
ere as f
3 ng/ml; quartile 3, 14.3 to 16.8 ng/ml; and quartile 4, 16.8 to 52.1 ng/ml.
DL  high-density lipoprotein.
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and lower eGFR (p for trend 0.0001 for all).
Clinical correlates of Gal-3. In multivariable analyses,
Gal-3 was positively associated with age, hypertension, body
mass index, prevalent coronary heart disease, and BNP, and
negatively associated with eGFR (Table 2). The R2 value of
this model was 0.15. There was a weak correlation between
Gal-3 and BNP (age- and sex-adjusted Pearson partial
correlation, r  0.05, p  0.002).
Among 2,425 participants who had usable echocardio-
graphic data, a 1 standard deviation increase in log Gal-3
was associated with 2-fold increased odds of having elevated
LV mass in age- and sex-adjusted analyses (95% confidence
interval [CI]: 1.33 to 3.08; p  0.001). When LV mass was
used as a continuous variable, higher Gal-3 remained
positively associated with higher LV mass (p  0.03). This
association was attenuated after adjustment for clinical
covariates (Table 3). Gal-3 was not associated with frac-
tional shortening, LV systolic dysfunction, or left atrial size.
Gal-3 and incident HF events. During a mean follow-up
period of 11.2 years, 166 patients (5.1%) experienced first
HF events. The crude HF incidence rate increased over
Gal-3 quartiles, with rates of 2.8, 3.8, 5.2, and 12.4 events
per 1,000 person-years in quartiles 1 through 4, respectively.
Figure 1 demonstrates higher cumulative incidence of HF
with increasing Gal-3 quartiles (log-rank test p  0.0001).
In age- and sex-adjusted analyses, a 1 standard deviation
Clinical Correlates of Gal-3 in 3,353 ParticipantsTable 2 Clinical Correlates of Gal-3 in 3,353 Participants
Correlate Coefficient Standard Error p Value
Age 0.222 0.019 0.0001
Antihypertensive treatment 0.180 0.039 0.0001
Body mass index 0.113 0.016 0.0001
Coronary heart disease 0.168 0.065 0.009
eGFR –0.141 0.017 0.0001
BNP 0.041 0.018 0.02
Log Gal-3 was standardized by sex. The regression coefficients indicate the increase in log Gal-3 in
the presence versus absence of the trait for dichotomous variables and per 1 standard deviation
increase for continuous variables (per 10-year increase in age, per 5.1 kg/m2 increase in body
ass index, per 0.26 increase in log eGFR, and per 0.90 increase in log BNP). The following
ariables were not significant in the stepwise selection model (p  0.05): systolic blood pressure,
iabetes, smoking, total and HDL cholesterol, valvular heart disease, and atrial fibrillation.
Abbreviations as in Table 1.
Gal-3 Associations With Echocardiographic TraiTable 3 Gal-3 Associations With Echocardio
Variable Model 1*
Dichotomous variable
Increased LV mass 2.02 (1.33–3.08)
LV systolic dysfunction 2.15 (0.99–4.65)
Continuous variables
LV mass 6.440 (2.880)
Fractional shortening –0.007 (0.005)
Left atrial dimension –0.004 (0.038)
Values are odds ratio (95% confidence interval) or coefficient (standard
a 1 SD increase in log Gal-3 level. *Adjusted for age and sex. Analyses f
for age, sex, diabetes, systolic blood pressure, antihypertensive medic
and left atrial dimension were adjusted for height, and left atrial dimension a
Gal-3  galectin-3; LV  left ventricular.increase in log Gal-3 was associated with a 28% increased
risk for incident HF (95% CI: 1.14 to 1.43, p  0.0001)
Table 4). After multivariable adjustment and the addition
f BNP, Gal-3 remained predictive of HF risk (hazard ratio
HR]: 1.23 per standard deviation increment in log Gal-3;
5% CI: 1.04 to 1.47; p  0.02). BNP in the same model
as associated with a 46% increased risk for HF (95% CI:
.23 to 1.75; p  0.0001). In analyses examining the
ssociation of Gal-3 quartile and incident HF, there was a
ignificant increase in HF risk across quartiles in age- and
ex-adjusted analyses (p  0.004), but this did not reach
tatistical significance after multivariable adjustment (p 0.11)
Online Table 1).
In secondary analyses, adjusting for eGFR had modest
mpact (multivariable-adjusted HR: 1.22; 95% CI: 1.01 to
.46; p  0.04; multivariable-adjusted and BNP-adjusted
R: 1.19; 95% CI: 0.99 to 1.42; p  0.06). Sensitivity
analyses excluding patients with prevalent CKD or adjust-
ing for the development of incident CKD attenuated the
association of Gal-3 and incident HF (p  0.05 for both).
Gal-3 and mortality. There were 468 deaths during the
follow-up period. Increasing Gal-3 quartiles were associated
with higher all-cause mortality, as displayed in the cumu-
lative incidence graphs in Figure 2. In age- and sex-adjusted
analyses, a 1 standard deviation increase in log Gal-3 was
associated with 24% increased risk for mortality (95% CI:
1.12 to 1.38; p  0.0001) (Table 4). This association
remained significant after accounting for clinical covariates
and BNP (HR: 1.14; 95% CI: 1.02 to 1.27; p 0.02). BNP
as associated with a similar risk for mortality in the same
odel (HR: 1.12; 95% CI: 1.01 to 1.24; p 0.03). The risk
or mortality increased across Gal-3 quartiles (p for trend 
.0007), and the fourth quartile was associated with 60%
ncreased hazards of mortality compared with the first
uartile (multivariable-adjusted and BNP-adjusted HR:
.62; 95% CI: 1.18 to 2.22; p  0.003) (Online Table 1).
In secondary analyses, Gal-3 was associated with cardio-
ascular death (98 events) in age- and sex-adjusted analyses
HR: 1.48; 95% CI: 1.21 to 1.82; p  0.0002). This
ssociation was partly attenuated after adjustment for clin-
cal covariates (multivariable-adjusted HR: 1.25; 95% CI:
2,425 Participantshic Traits in 2,425 Participants
p Value Model 2† p Value
0.001 1.54 (0.99–2.38) 0.06
0.05 1.72 (0.75–3.93) 0.20
0.03 1.700 (2.804) 0.54
0.14 –0.007 (0.004) 0.14
0.91 –0.062 (0.037) 0.09
Odds ratios and regression coefficients denote change associated with
ass and left atrial dimension were also adjusted for height. †Adjusted
nd previous myocardial infarction. Additionally, analyses for LV massts ingrap
error).
or LV m
ation, analyses were adjusted for valvular heart disease.
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adjusted HR: 1.21; 95% CI: 0.98 to 1.49; p  0.08).
The exclusion of individuals with prevalent CKD did not
attenuate the association of Gal-3 with mortality (multivariable-
adjusted HR: 1.21; 95% CI: 1.08 to 1.36; p  0.0009), and
the association persisted after further adjusting for incident
CKD (HR: 1.25; 95% CI: 1.10 to 1.43; p  0.0008).
Performance of Gal-3 as a biomarker. When added to the
clinical model for HF, Gal-3 did not substantially increase
the C-statistic (0.855 to 0.859), with similar findings in the
prediction of all-cause mortality (Table 5). Improvements in
the IDI and relative IDI were small and comparable to the
addition of BNP alone into the clinical model for mortality.
The category-free NRI for the addition of Gal-3 in pre-
Figure 1 HF and Gal-3 Quartiles
The cumulative incidence of heart failure (HF) increased with higher galectin-3 (Ga
Association of Plasma Gal-3 Levels,Incident HF, and MortalityTable 4 Association of Plasma Gal-3 Levels,Incident HF, and Mortality
Outcome Model HR (95% CI) p Value
Incident HF
Age and sex adjusted 1.39 (1.17–1.65) 0.0002
Multivariable adjusted* 1.27 (1.06–1.52) 0.01
Multivariable adjusted
 BNP
1.23 (1.04–1.47) 0.02
All-cause mortality
Age and sex adjusted 1.25 (1.12–1.39) 0.0001
Multivariable adjusted* 1.15 (1.04–1.29) 0.01
Multivariable adjusted
 BNP
1.14 (1.03–1.28) 0.02
Hazard ratios (HRs) and 95% confidence intervals (CIs) denote hazard associated with a 1 SD
ncrease in log Gal-3 levels. This increase is equivalent to comparing a Gal-3 level of 14.0 ng/ml
sample mean) with a level of 18.1 ng/ml. *Adjusted for age, sex, systolic blood pressure,
ntihypertensive treatment, bodymass index, diabetesmellitus, smoking, prevalent coronary heart
isease, atrial fibrillation, and valvular heart disease. Mortality analyses were additionally adjusted
or eGFR and total and HDL.
HF  heart failure; other abbreviations as in Table 1.dicting HF was 0.20 (95% CI: 0.02 to 0.40), representing a
weak effect size. Similar magnitudes were observed for the
category-free NRI in the prediction of all-cause mortality.
Gal-3 in HF with preserved versus reduced ejection
fraction. Of 166 participants with incident HF events, 140
(84%) underwent assessment of LV function at or around
the time of HF onset. Of these, 63 were classified as having
HF with preserved ejection fraction and 77 as having HF
with reduced ejection fraction. There was no difference in
baseline Gal-3 levels in participants who developed HF
with preserved versus reduced ejection fraction (16.3  4.5
ng/ml vs. 15.8  4.2 ng/ml, respectively, p  0.54).
Discussion
Our findings demonstrate that higher levels of Gal-3, a
marker of cardiac fibrosis, are associated with an increased
risk for incident HF and all-cause mortality in the commu-
nity. Previous studies have examined the prognostic value of
Gal-3 in patients with existing HF. To our knowledge, our
study is the first to report the association of Gal-3 with risk
for new-onset HF in apparently healthy subjects. Our data
also suggest that the association of Gal-3 with incident HF
may be influenced by kidney function. Further studies on
the link between Gal-3, kidney function, and myocardial
injury and fibrosis will help elucidate the potential role of
Gal-3 in the pathophysiology of HF.
Gal-3 is emerging as a prognostic biomarker in patients
with HF (8–11,27,28). More recently, higher Gal-3 levels
were found to be associated with all-cause mortality in a
community-based cohort (12). Our findings substantiate
the prognostic role of Gal-3 with respect to all-cause
artiles.l-3) qumortality. Gal-3 is an indicator not only of myocardial
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Galectin-3 and Incident Heart Failure October 2, 2012:1249–56fibrosis but also other fibrotic conditions, including liver
cirrhosis (29,30) and pulmonary fibrosis (31), all of which
could increase the risk for overall mortality. Beyond the
association with all-cause mortality, a recent case-control
study demonstrated an association of Gal-3 with HF risk
after acute coronary syndromes (32). Ours is the first study
to extend these findings to a longitudinal cohort of osten-
sibly healthy subjects and to demonstrate the role of Gal-3
as a predictor of new-onset HF in the community.
Experimental evidence suggests that Gal-3 may be a
mediator of fibrosis (33). Gal-3 is up-regulated in a number
of human fibrotic disease entities, including liver cirrhosis
(29,30) and pulmonary fibrosis (31). Gal-3/ mice are
rotected against hepatic and renal fibrosis, and Gal-3
ppears to be required for transforming growth factor–beta–
ediated myofibroblast activation and matrix production
Figure 2 Mortality and Gal-3 Quartiles
The cumulative incidence of all-cause mortality increased with higher galectin-3 (G
Performance Metrics of Gal-3 in Risk Prediction ModelsTable 5 Performance Metrics of Gal-3 in Risk Prediction Mode
C-Statistic (95% CI) ID
Incident HF
Clinical model* 0.855 (0.823 to 0.887)
Clinical model  Gal-3 0.859 (0.828 to 0.890) 0.001 (
Clinical model  BNP 0.869 (0.839 to 0.898) 0.007 (
Clinical model  BNP  Gal-3† 0.871 (0.842 to 0.900) 0.001 (
All-cause mortality
Clinical model* 0.785 (0.762 to 0.808)
Clinical model  Gal-3 0.786 (0.763 to 0.809) 0.001 (
Clinical model  BNP 0.785 (0.762 to 0.808) 0.002 (
Clinical model  BNP  Gal-3† 0.786 (0.763 to 0.809) 0.001 (
*Clinical model includes age, sex, systolic blood pressure, antihypertensive treatment, body mass
disease. Mortality analyses were additionally adjusted for prevalent HF, eGFR, and total and HDL c
model or to the clinical model plus BNP.
IDI  integrated discrimination improvement; NRI  net reclassification improvement; other abbrevia30,34). Gal-3 is the most overexpressed gene in transgenic
en-2 rats that rapidly progress to HF (6). Gal-3 is
xpressed in activated macrophages, with binding sites
ocalized to the myocardial extracellular matrix and cardiac
broblasts, where it induces fibroblast proliferation, collagen
eposition, and ventricular dysfunction (6). Infusion of
al-3 into the pericardial space leads to cardiac dysfunction
n rats, a process that appears to be mediated via the
ransforming growth factor–beta/Smad3 signaling pathway
7). In clinical studies, Gal-3 is correlated with markers of
xtracellular matrix turnover, supporting its role in collagen
etabolism (35).
This collective experimental evidence suggests that Gal-3
ay play a causal in cardiac remodeling. Although the
ncremental prognostic value of adding Gal-3 to existing
linical risk factors, particularly above and beyond BNP, was
uartiles.
CI) Relative IDI (95% CI) Category-Free NRI (95% CI)
to 0.005) 0.014 (–0.022 to 0.052) 0.203 (0.018 to 0.397)
to 0.017) 0.070 (–0.021 to 0.164) 0.290 (0.110 to 0.473)
to 0.005) 0.011 (–0.023 to 0.044) 0.162 (–0.028 to 0.360)
to 0.004) 0.007 (–0.008 to 0.021) 0.184 (0.066 to 0.297)
to 0.004) 0.009 (–0.004 to 0.022) 0.108 (–0.011 to 0.226)
to 0.003) 0.004 (–0.010 to 0.018) 0.178 (0.066 to 0.291)
diabetes mellitus, smoking, prevalent coronary heart disease, atrial fibrillation, and valvular heart
rol. †IDI, relative IDI, and category-free NRI represented are for the addition of Gal-3 to the clinicalal-3) qls
I (95%
–0.002
–0.002
–0.002
–0.001
–0.001
–0.002
index,
holestetions as in Tables 1, 3, and 4.
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pathobiological rather than prognostic in nature. Our find-
ings are consistent with the notion that active fibrosis may
precede clinical manifestations of HF by many years. Al-
though most HF therapies are initiated late in the course of
the disease, the identification of fibrosis before impairment
of LV function may offer a window of opportunity to
initiate targeted preventive treatment early in the course of
the disease. Because of its putative role as a mediator of
fibrosis, directly modulating the Gal-3 pathway may be
beneficial. Gal-3 levels can be modulated with modified
citrus pectin, a soluble dietary fiber found in citrus fruit (36).
This pectin derivative can bind to the carbohydrate recog-
nition domain of Gal-3, altering its bioactivity (37). Treat-
ment with modified citrus pectin decreased Gal-3 expres-
sion and significantly attenuated renal fibrosis and
inflammation in an animal model of acute kidney injury
(38), and future studies examining the effect of Gal-3
inhibition on cardiovascular end points would be of high
interest.
Notably, we observed a strong association of Gal-3 with
kidney dysfunction, a finding that has been corroborated by
previous studies in patients with and without existing HF
(10,12,28,39). We also found that adjusting for kidney
function attenuated the association of Gal-3 with incident
HF events. This is consistent with prior studies in HF, in
which adjustment for kidney function appeared to attenuate
in part the prognostic impact of Gal-3 (39) and in which the
association of Gal-3 with kidney function appeared to
overshadow associations with cardiac structure and function
(28). It may be that worsening kidney function mediates
Gal-3 effects on cardiac remodeling and HF. Alternatively,
elevated levels of Gal-3 in both the kidney and the heart
may lead to HF, and consequently adjustment for kidney
function may obscure the association of Gal-3 with HF risk.
We found that Gal-3 was associated with elevated LV
mass in age-adjusted and sex-adjusted analysis, although
this relation was only marginally significant in multivariable
analyses. Gal-3 may be a stronger prognostic marker in
those with preserved compared with reduced ejection frac-
tions (39), and Gal-3 levels have been associated with
measures of diastolic function in patients presenting with
acute decompensated HF (11). Biologically, it is plausible
that a matrix and fibrosis marker such as Gal-3 may play a
more prominent role in those with HF with preserved
ejection fraction. However, in exploratory analyses, we
found no difference in baseline Gal-3 concentrations in
participants who eventually developed HF with preserved
versus reduced ejection fraction.
Study limitations. Although the addition of Gal-3 to
clinical factors resulted in improved classification as assessed
by the category-free NRI, changes in the C-statistic and
IDI were negligible. It may be that Gal-3 in combination
with other novel biomarkers in a multimarker approach
might be useful, and the comparison of Gal-3 with other
emerging biomarkers of HF, such as high-sensitivity tro-ponin, N-terminal pro-BNP, and soluble ST2 will need to
be explored in future studies. The number of HF events was
modest and likely limited our power to conduct quartile
analyses or other more complex analyses examining the role
of kidney function in the association of Gal-3 and HF. In
addition to its role in fibrosis in several organ systems, Gal-3
has also been associated with tumorigenesis in thyroid
cancer and other malignancies (40). Circulating Gal-3 levels
have not been elevated in these conditions (41), but we
cannot exclude the possibility that Gal-3 might act in
several pathophysiologic pathways to increase mortality risk.
Although secondary analyses demonstrate a suggestive as-
sociation with cardiovascular death, Gal-3 may still reflect
noncardiac processes. Further elucidation of Gal-3 in rela-
tion to cardiac remodeling, including more sensitive mea-
sures of diastolic function or direct measures of cardiac
fibrosis would be of great interest in future studies. Last, our
study was limited to a predominantly white study sample,
limiting generalization to other populations.
Conclusions
Higher circulating Gal-3 concentrations are associated with
increased risk for new-onset HF and all-cause mortality in
the community. Future potential clinical uses of Gal-3
measurement might include the identification of asymp-
tomatic subjects with early evidence of cardiac fibrosis, in
whom targeted therapies may be useful to delay the onset of
HF. Animal data suggest that Gal-3 is a mediator of
fibrosis, and directly targeting the Gal-3 pathway may
represent a future preventive treatment strategy.
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